Acquired Resistance Is Oncogene and Drug Agnostic

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Tumor agnostic therapies targeting specific oncogenic drivers, such as TRK inhibitors, represent a significant advancement in precision oncology.
• These therapies have shown efficacy across various cancer types harboring specific genetic alterations, irrespective of tumor histology.
• Understanding resistance mechanisms is crucial for improving long-term treatment outcomes.

Purpose of the Study:

• To investigate common resistance mechanisms to TRK inhibitors across different tumor types.
• To identify recurring patterns in acquired resistance, including genetic mutations and signaling pathway alterations.
• To inform future therapeutic strategies aimed at overcoming or preventing treatment resistance.

Main Methods:

• Analysis of acquired resistance data from preclinical and clinical studies involving TRK inhibitors.
• Genomic profiling to identify kinase domain mutations associated with resistance.
• Investigation of bypass signaling pathways, including the RTK-RAS-RAF-MAPK pathway, in resistant models.

Main Results:

• Acquired resistance to TRK inhibitors frequently involves recurrent mechanisms.
• Common resistance mechanisms include specific kinase domain mutations within the TRK family.
• Activation of bypass signaling pathways, notably the RTK-RAS-RAF-MAPK pathway, is a prevalent resistance mechanism.
• These resistance mechanisms appear to be conserved across different tumor types, oncogenes, and TRK inhibitors.

Conclusions:

• Resistance to TRK inhibitors is often driven by predictable and recurring molecular alterations.
• The identified resistance mechanisms, including kinase mutations and bypass signaling, pose a challenge to durable responses in tumor agnostic therapy.
• Further research is needed to develop strategies to overcome or circumvent these resistance mechanisms for sustained therapeutic benefit.